Orient Pharma Co's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 45.77.
Orient Pharma Co's Days Inventory for the
three
months ended in Dec. 2025 was 174.59.
Orient Pharma Co's Days Payable for the
three
months ended in Dec. 2025 was 33.95.
Therefore, Orient Pharma Co's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2025 was 186.41.
Orient Pharma Co (ROCO:4166) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Orient Pharma Co Cash Conversion Cycle Related Terms
Orient Pharma Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4166 vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Cash Conversion Cycle falls into.
Orient Pharma Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Orient Pharma Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Pharma Co (ROCO:4166) has a Cash Conversion Cycle of 186.41 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Orient Pharma Co and its competitors.
Is Orient Pharma Co's Cash Conversion Cycle too high?
Orient Pharma Co's current Cash Conversion Cycle is 186.41. The Drug Manufacturers industry median Cash Conversion Cycle is 146.14. Orient Pharma Co's value of 186.41 is 27.6% above this industry median. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Cash Conversion Cycle compare to ZTS and UTHR?
Orient Pharma Co's Cash Conversion Cycle of 186.41 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 146.14. Orient Pharma Co's value of 186.41 is 27.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 146.14, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Cash Conversion Cycle of 186.41 is 27.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 146.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Cash Conversion Cycle is 186.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Cash Conversion Cycle is 186.41 and 27.6% above the Drug Manufacturers industry median of 146.14. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Cash Conversion Cycle is 186.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Cash Conversion Cycle: 186.41
GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
Industry Position: 27.6% above the Drug Manufacturers median
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score
Get the complete analysis for ROCO:4166
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
